• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Quotient Sciences

    Almac Group

    Syngene

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Almac Group

    Reed-Lane

    Emergent BioSolutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Artificial Intelligence and Machine Learning in Healthcare

    Because your summertime reading should make you a little uncomfortable.

    Artificial Intelligence and Machine Learning in Healthcare
    Related CONTENT
    • Re-Open Your Tool Chest
    • Sanofi and Google to Develop Innovation Lab
    • The Future Is… Therapeutic
    • The Manufacturing Revolution In Medicine
    • Improving Your Development Program
    Ben Locwin, PhD, MBA, MS, Contributing Editor07.15.19
    We are now in the future—where artificial intelligence (AI) and machine learning (ML) are components of our overall healthcare strategy for humanity. This was at least the future as far as the past was concerned. Now we see the limitations of AI and ML and it’s our job to enhance both to make how we perceive our current visions of ‘the future’ (according to now) to be the most effective it can be for the identification and mitigation of diseases and disorders.

    Artificial intelligence and machine learning
    These aren’t synonymous terms, so rule #1 is to stop using them both interchangeably as though they are. Artificial intelligence is a broader term within which machine learning resides. Machine learning is a subset in which a computer program can be fed data which it incorporates into its algorithmic structure to make better and better predictions about future problems posed to it.

    AI and machine learning are both best-suited to identify high-data situations that certainly could be solved by humans, but for which that solution or set of solutions would require the review and synthesis of thousands of pages (or more) worth of data, and would be prohibitive for people to actually do. A good current example of the use of AI (really ML) in healthcare is Google’s system to better detect lung cancer. According to the American Cancer Society, lung cancer is the current leading cause of cancer deaths for both men and women. Out of an estimated 228,000 new cases that will be identified this year, there will be an estimated 143,000 deaths. To address this need, machine learning is being trialed to help improve the current, ridiculously-low hit-rate, diagnostic technology better serve patients who may have lung cancer.

    Here’s the background: Lung cancer screening currently involves low-dose CT scanning, and has a 96% false positive rate. On a lung CT scan, about one quarter of images reveal shadowing features which are consistent with nodules in the lung. Of those results, however, fewer than 4% of patients actually have lung cancer. This creates unnecessary anxiety, unneeded further testing—likely more invasively and not risk-free—and a degradation in patient global health status. When putting computation to the test, the machine learning that was used in the study was able to correctly identify every actual positive case of cancer, and in one of the larger tests, the Google machine learning protocol outperformed 6 radiologists reading the same results by identifying 5% more actual cancer cases. At the same time, the algorithm rejected about 11% of the false positives—a previous study published in the journal Thorax found that false positives were reduced by about 30%. This is sparing the patients from undergoing further unnecessary medical procedures, some of which have resulted in death even though the patient actually had no cancer.

    If you take a look at Figure 1 you’ll see that machine learning is nested within artificial intelligence as a subset, and deep learning is itself a subtype of machine learning. If you’ve missed out on the happenings of artificial intelligence over the past thirty or so years, you may have not noticed that ‘deep learning’ was a thing. Deep learning refers to a type of machine learning that occurs across networks, and is one of the reasons that IBM codenamed one of their learning machines ‘Deep Blue,’ which it pitted against world chess grandmaster Garry Kasparov in a series of high-tension chess matches in 1996-1997; the old human-versus-computer showdown writ large. Spoiler alert: IBM’s supercomputer won. On this topic of machines taking over the world at the expense of people, some vocal pundits have taken their opinions of AI and ML to the media to make outrageous claims that AI is going to destroy humanity if we aren’t careful. The reality is far more prosaic and it’s probabilistically very unlikely that it will pose a direct threat to us. It’s unfortunate, but the people who give public opinions about AI or machine learning are spectacularly uninformed.


    Figure 1: Artificial Intelligence, Machine Learning, Deep Learning

    Using AI and ML for pharma applications
    Big data analytics, in silico drug design and molecular modeling, and trial risk prediction—a subset of predictive analytics—are all right within the sweet spot of machine learning for pharmaceutical development and deployment. Previously, I’ve worked on a publication which included risk assessment and in silico development tools (referenced below) and it offered absolute cutting-edge approaches to some of these challenges by some of the most luminary thinkers in different aspects of the field. The future only gets brighter and brighter for these applications, and there is only one thing standing in the way that I see which stands out among all other challenges: Algorithmic opacity.

    Tending to the details of AI and ML (and DL)
    We do need to understand better what some of the algorithms are actually doing, when they start assembling learning strategies on their own. This is what I mean by algorithmic opacity. For example, recent cosmological modeling of computers done with the help of a type of machine learning led to very accurate results of a virtual version of the cosmos in an incredibly short amount of time. When the programmers and researchers tried to reverse-engineer what exactly was the computational path that led to such accurate results (and so quickly), what they quickly found was that they had no idea what the algorithmic process was. Maybe the principle of parsimony was involved in the calculations. Maybe not.

    It can be deviously difficult to ferret-out what the decision-making process was which led an in silico model to return one favorable alternative instead of another. Sometimes impossible. And this is a HUGE extant problem for us. If you haven’t spent a sleepless night over this yet, perhaps plan on not sleeping tonight as you think through the implications. For a highly-regulated industry, not knowing how a decision was reached which used available data is very problematic.

    Also, as these technologies are rolled out to greater and greater effect clinically, not knowing the reason behind particular decisions is very troubling. This requires unwinding certain decisions post hoc and a posteriori; which is philosophically almost bordering on anti-science. Add to this that for the European markets, GDPR requires “meaningful information of the logic involved” when automated decision-making takes place (Articles 13, 14 and 15). Helping patients will be threatened with being hamstrung by political motivations if we can’t reduce the algorithmic opacity. 

    References
    • American Cancer Society. (2019). Lung cancer. https://www.cancer.org/cancer/lung-cancer.html
    • Ardila, D. et al. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25, 954-961.
    • Zurdo, J. et al. (2015). Developability of Biotherapeutics: Computational Approaches. https://www.crcpress.com/Developability-of-Biotherapeutics-Computational-Approaches/Kumar-Kumar-Singh/p/book/9781482246131 


    Ben Locwin, PhD, MBA, MS

    Ben Locwin is a healthcare futurist and industry executive, having worked in pharmaceuticals, medical devices, and medical technologies to improve the balance of care available to patients. Says Dr. Locwin, “Every single patient that receives medical care is exposed to at least one drug therapy or device as part of the course of diagnosis and treatment. We have the direct opportunity and moral imperative to make these approaches better and safer for the future.”
    Related Searches
    • cancer
    • Testing
    • Development
    • ibm
    Suggested For You
    Re-Open Your Tool Chest Re-Open Your Tool Chest
    Sanofi and Google to Develop Innovation Lab Sanofi and Google to Develop Innovation Lab
    The Future Is… Therapeutic The Future Is… Therapeutic
    The Manufacturing Revolution In Medicine The Manufacturing Revolution In Medicine
    Improving Your Development Program Improving Your Development Program
    CPhI NA Keynotes: Former Senator Jeff Flake & Numerate CTO Brandon Allgood CPhI NA Keynotes: Former Senator Jeff Flake & Numerate CTO Brandon Allgood
    CENTOGENE Appoints AI Director CENTOGENE Appoints AI Director
    Three Key Challenges for Wide-Scale AI Adoption in Pharma Three Key Challenges for Wide-Scale AI Adoption in Pharma
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    Career Inflection Points Career Inflection Points
    Leveraging Deep Learning in Drug Research Leveraging Deep Learning in Drug Research
    Celgene Enters AI Drug Discovery Deal with Exscientia Celgene Enters AI Drug Discovery Deal with Exscientia
    Synthetic Control Arms Synthetic Control Arms
    2019 Trends & Predictions 2019 Trends & Predictions
    Implementing AI in Drug Discovery Implementing AI in Drug Discovery

    Related Columns

    • Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown and Joe Rymsza, IQVIA 03.01.21

    • Information Technology
      Probing the Limits of Pharma’s Future

      Probing the Limits of Pharma’s Future

      A retrospective on the past 20 years and a prospective on where the future will take us.
      Ben Locwin, Contributing Writer 10.15.19

    • Information Technology
      My Head is in The Cloud(s)

      My Head is in The Cloud(s)

      Cloud computing is making it easier to control all aspects of the global pharma production process
      Emil W. Ciurczak, DoraMaxx Consulting 05.07.19


    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Information Technology
      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18

    • cGMP Manufacture | Information Technology
      Flexible Manufacturing Strategies and Data Integrity

      Flexible Manufacturing Strategies and Data Integrity

      Making processes integral with your data handling ability
      Emil W. Ciurczak, DoraMaxx Consulting 11.07.17


    • Drug Development | Drug Discovery

      The Trials and Tribulations of Male Contraception

      Where has research led in the search for effective oral male contraception?
      Adele Graham-King, Contributing Editor 03.07.17

    • Drug Development | Drug Discovery | R&D

      Taking the Wheeze Out of Asthma

      Novartis’ fevipiprant looks like a promising asthma treatment on the horizon
      Adele Graham-King, Contributing Editor 09.08.16

    • Drug Development | Drug Discovery

      How ‘Mush-room’ For Improvement in Antibiotic Production?

      The medical world is acutely aware of the issues on the horizon with regards to antibiotic resistance
      Adele Graham-King, Contributing Editor 06.02.16


    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • APIs | Information Technology
      India’s Pharmaceutical Industry Outlook

      India’s Pharmaceutical Industry Outlook

      Market predicted to be worth $50B by 2020
      Dr. Gurpreet Sandhu, Reva Pharmachem 03.06.15

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Executive Moves: Novavax
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    Breaking News
    • BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login